Litvan I
Neuropharmacology Unit, Defense & Veteran Head Injury Program, Henry M. Jackson Foundation, Bethesda, Maryland 20817-1844, USA.
Semin Neurol. 2001;21(1):41-8. doi: 10.1055/s-2001-13118.
Because of the relevance of an early and accurate diagnosis for prognosis, management, and participation of patients in research, the classical clinical features--features that should raise suspicion of progressive supranuclear palsy (PSP) and those that should make the diagnosis of PSP unlikely--are discussed in this article. The accuracy of currently used clinical diagnostic criteria and the role of laboratory investigations in the diagnosis of PSP are reviewed. New terminology for the clinical diagnostic criteria for PSP is proposed. The main neuropathologic and neurochemical features supporting current main symptomatic and hypothesized experimental biologic therapies are suggested.
鉴于早期准确诊断对于患者预后、治疗管理以及参与研究的重要性,本文将讨论经典临床特征——即那些应引发对进行性核上性麻痹(PSP)怀疑的特征以及那些使PSP诊断不太可能成立的特征。同时,还将回顾当前使用的临床诊断标准的准确性以及实验室检查在PSP诊断中的作用。文中提出了PSP临床诊断标准的新术语。并给出了支持当前主要症状性和假设性实验性生物疗法的主要神经病理学和神经化学特征。